Comparison of clinical efficacy and safety of argatroban and tirofiban in the treatment of progressive cerebral infarction
YANG Bin
ZHANG Chunyang
LI Yanling
LI Dongmei
LI Hong
JIN Aojie
Abstract：Objective To compare the clinical efficacy and safety of argatroban and tirofiban in the treatment of pa-tients with progressive cerebral infarction(PCI).Methods Eighty patients with PCI were enrolled in this study and were divided into the argatroban group and the tirofiban group(40 cases per group)using a random number table method.Patients in the argatroban group were immediately administered argatroban injection upon admission.For the first 2 days,60 mg of argatroban injection was diluted in 500 mL of 0.9%sodium chloride injection for intravenous infusion,with the infusion duration lasting no less than 24 h per day.For the subsequent 5 days,the dosage was adjusted to 20 mg of argatro-ban injection diluted in 100 mL of 0.9%sodium chloride injection,and the infusion duration was set at no less than 3 h per day.Patients in the tirofiban group were treated with tirofiban injection immediately after admission,with a single dose regimen of 12.5 mg of tirofiban injection diluted in 250 mL of 0.9%sodium chloride injection for a continuous intravenous infusion of 48 h.Both groups received combined basic therapy starting from the 3rd day of treatment.The National Insti-tutes of Health Stroke Scale(NIHSS)was adopted to evaluate the degree of neurological deficit before treatment and on the 14th day after treatment initiation.A 3-month follow-up was conducted,and the modified Rankin Scale(mRS)score was used to assess the patients'prognosis.Routine blood tests,liver and kidney function tests,and coagulation function pa-rameters were measured in both groups before and after treatment.Additionally,the incidence of severe bleeding events and drug-related adverse reactions were recorded throughout the treatment period and the 3-month follow-up.Results After 14 days of treatment,the NIHSS scores of both groups were significantly lower than those before treatment(both P<0.05),and the NIHSS score of the tirofiban group was lower than that of the argatroban group(P<0.05).During 3 months of follow-up,the mRS scores of both groups significantly decreased in comparison with those before treatment(both P<0.05),and the mRS score of the tirofiban group was lower than that of the argatroban group(P<0.05).At 3 months of fol-low-up,the proportion of functional independence in the tirofiban group was higher than that in the argatroban group(P<0.05),while there was no statistically significant difference in the proportion of severe disability between the two groups(P>0.05).Before and after treatment,the blood routine,liver and kidney function,and coagulation function indexes of both groups were normal.During the treatment period and within 3 months of follow-up,no severe bleeding events such as symptomatic intracerebral hemorrhage,gastrointestinal bleeding,or gingival bleeding occurred in either group;only 1 pa-tient in each group developed mild subcutaneous ecchymosis,which resolved spontaneously without special treatment.Conclusions Both argatroban and tirofiban can effectively improve the neurological deficit and long-term prognosis of pa-tients with PCI in the early treatment,with good safety and no increased risk of bleeding.Tirofiban has more advantages in promoting neurological function recovery and improving prognosis.
Keywords：progressive cerebral infarctionargatrobantirofibanneurological functionsafety
Publication Date：2026-02-25
Online Publishing Date：2026-03-19(First online date of this platform, not the publication date of the document)
Pages：4( 56-59 )